Cyclica

Back to Companies Directory

Cyclica (acquired by Recursion Pharmaceuticals)

Website
https://cyclicarx.com/

Founded
2013

Technologies

AI Companies (Drug Discovery)

Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of disease.

Our computational approach to polypharmacology is unique in the industry. We use a proteome-wide lens to evaluate multiple novel and rare on and off-target interactions simultaneously.

We’re also the only company of our kind that integrates science to advance molecules downstream. A structure-based view keeps our work accountable to biology, chemistry, physics, and genomics.

To learn more about Cyclica and how we partner, please visit www.cyclicarx.com

Cyclica. From molecule to medicine.

Articles Mentioning This Company

Cyclica's Chemical Probes for DCAF1

Cyclica is designing chemical probes for DCAF1, a potentially novel target for protein degradation, with proprietary technology MatchMaker DCAF1 was originally identified as a putative antiviral host target and more broadly as a promising target to facilitate proteasome-mediated degradation of therapeutic targets as a part of a E3 ubiquitin ligase …

Technology Meets Biology in Canada

Over the past decade, Canada emerged as a promising global location for drug discovery and biotech business, especially when it comes to applying advanced technologies, such as artificial intelligence (AI) and quantum computing in life sciences.

Toronto Startups Develop AI for Drug Discovery

Toronto’s Blossoming AI-driven Drug Discovery Scene

Canada has established itself as a rapidly growing global hub for artificial intelligence (AI) innovation and commercialization. This roots deep into the history of early programs and funding provided by Canadian Institute for Advanced Research (CIFAR) and the Natural Sciences and Engineering Research Council of Canada (NSERC) to such AI …